SB Investment Advisers (UK)’s Roivant Sciences ROIV Stock Holding History

SB Investment Advisers (UK)’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,671,732	Closed	-$74M	–	10
2026 Q1	$74M	Sell	2,671,732 -13,741,871	-84%	-$353M	0.96%	7
2025 Q4	$356M	Sell	16,413,603 -23,901,524	-59%	-$472M	3.56%	3
2025 Q3	$610M	Sell	40,315,127 -19,637,525	-33%	-$243M	4.6%	3
2025 Q2	$676M	Sell	59,952,652 -1,900,066	-3%	-$20.6M	5.36%	3
2025 Q1	$624M	Sell	61,852,718 -204,819	-0.3%	-$2.21M	5.69%	3
2024 Q4	$734M	Sell	62,057,537 -3,876,537	-6%	-$45.8M	6.45%	3
2024 Q3	$761M	Sell	65,934,074 -5,427,314	-8%	-$61.8M	6.27%	3
2024 Q2	$754M	Sell	71,361,388 -1,670,279	-2%	-$18.3M	6.97%	3
2024 Q1	$770M	Hold	73,031,667	–	–	7.6%	4
2023 Q4	$820M	Hold	73,031,667	–	–	7.3%	4
2023 Q3	$853M	Sell	73,031,667 -10,000,000	-12%	-$113M	7.03%	3
2023 Q2	$837M	Hold	83,031,667	–	–	6.38%	4
2023 Q1	$613M	Sell	83,031,667 -12,000,000	-13%	-$98.8M	5.04%	4
2022 Q4	$759M	Sell	95,031,667 -4,343,919	-4%	-$24.2M	6.33%	4
2022 Q3	$320M	Hold	99,375,586	–	–	2.45%	6
2022 Q2	$404M	Hold	99,375,586	–	–	3.21%	8
2022 Q1	$491M	Hold	99,375,586	–	–	2.33%	9
2021 Q4	$1B	Buy	+99,375,586	New	+$827M	2.92%	6

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

SB Investment Advisers (UK)'s ROIV Position: Q2 2026 in Review

SB Investment Advisers (UK) sold out of Roivant Sciences (ROIV) in Q2 2026, closing a stake of 2,671,732 shares — an estimated $74M sold.

SB Investment Advisers (UK) first reported a position in ROIV in Q4 2021 and held it in 18 quarters. The position peaked at $1B in Q4 2021. 499 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

SB Investment Advisers (UK) reported no remaining Roivant Sciences position as of Q2 2026 after selling out during the quarter.
SB Investment Advisers (UK) sold 2,671,732 Roivant Sciences shares in Q2 2026, an estimated $74M.
SB Investment Advisers (UK) first reported a position in Roivant Sciences in Q4 2021 and held it in 18 quarters.
SB Investment Advisers (UK)'s Roivant Sciences position peaked at $1B in Q4 2021.
499 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on SB Investment Advisers (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.